Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy
Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy
To register for today's webinar click here.
要註冊今天的網絡研討會，請單擊此處。
Linius Technologies Ltd (ASX:LNU) has signed a second US college conference and its first deployment in American football. The agreement is to provide its Whizzard sports solution to the Lone Star Conference (LSC). The LSC is the first customer to deploy Linius Media Solutions for American Football. The agreement is for an initial 3 year term. Linius CEO, James Brennan said "We are excited to be working with the LSC, the premier NCAA Division II conference. As our first customer deployment for American football, it provides an important entry into the most highly monetised sport in the US. Unleashing the value of football archives is a top priority for Linius." Shares are trading flat at 0.2 cents.
Linius Technologies Ltd（澳大利亞證券交易所股票代碼：LNU）已經簽署了第二屆美國大學會議，這是它在美式足球領域的首次部署。該協議旨在爲孤星聯盟（LSC）提供其Whizzard體育解決方案。LSC是第一個爲美式足球部署Linius媒體解決方案的客戶。該協議的初始期限爲3年。萊尼烏斯首席執行官詹姆斯·布倫南表示：“我們很高興能與LSC合作，這是NCAA第二分區的頂級會議。作爲我們在美式足球領域的首次客戶部署，它爲進入美國收入最高的體育項目提供了重要入口。釋放足球檔案的價值是Linius的當務之急。”股價持平至0.2美分。
Biotron Limited (ASX:BIT) has annouced preliminary analyses of data from the BIT225-010 Phase 2 clinical trial of the Company's lead antiviral drug BIT225 provide confirmation, and extension, of the results of previous trials in people infected with HIV-1. Study participants were followed for a one month period following 24-weeks of BIT225 or placebo dosing; all individuals continued on cART as per standard treatment guidelines post-study. The primary objectives of the trial were to evaluate the safety, efficacy and impact of BIT225 administered with cART on selected inflammatory and immune markers in this patient population. Shares are trading 22.67 per cent higher at 9.2 cents.
Biotron Limited（澳大利亞證券交易所股票代碼：BIT）宣佈，對該公司主要抗病毒藥物 BIT225 的 BIT225-010 二期臨床試驗數據的初步分析證實並擴展了先前針對 HIV-1 感染者的試驗結果。在 BIT225 或安慰劑給藥 24 周後，對研究參與者進行了爲期一個月的隨訪；根據研究後的標準治療指南，所有個體都繼續服用 cART。該試驗的主要目標是評估與 cART 一起使用的 BIT225 對該患者群體中選定的炎症和免疫標誌物的安全性、有效性和影響。股價上漲22.67％，至9.2美分。
Elixir Energy (ASX:EXR) has provided an operations update on its 100% owned Grandis project located in Queensland, adjacent to the Wallumbilla gas hub. Following a recent successful suite of Diagnostic Formation Integrity Tests conducted at Daydream-2, the Company decided to test the free-flowing capacity of the Lorelle Sandstone between 4,200 and 4,217 metres. The test has been highly successful – with a maximum rate of 2.3 Million Standard Cubic Feet Per Day and stabilised flow rate of 1.3 Million Standard Cubic Feet Per Day. Elixir understands this is the deepest unstimulated flow of gas in onshore Australia East of the Perth Basin. Shares are trading 29.58 per cent higher at 9.2 cents.
Elixir Energy（澳大利亞證券交易所股票代碼：EXR）提供了其100％控股的Grandis項目的最新運營情況，該項目位於昆士蘭州，毗鄰瓦倫比拉天然氣樞紐。繼最近在Daydream-2成功進行了一系列診斷形成完整性測試之後，該公司決定測試洛雷爾砂岩在4,200至4,217米之間的自由流動能力。該測試非常成功——最大流量爲每天230萬標準立方英尺，穩定流速爲每天130萬標準立方英尺。Elixir知道這是珀斯盆地以東澳大利亞陸上最深的未受刺激的天然氣流。股價上漲29.58％，至9.2美分。
